Theratechnologies Valuation

THTX Stock  USD 3.14  0.01  0.32%   
At this time, the company appears to be overvalued. Theratechnologies has a current Real Value of $2.47 per share. The regular price of the company is $3.14. Our model measures the value of Theratechnologies from inspecting the company fundamentals such as Shares Outstanding of 45.98 M, return on equity of -11.17, and Operating Margin of 0.1 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
3.14
Please note that Theratechnologies' price fluctuation is very risky at this time. Calculation of the real value of Theratechnologies is based on 3 months time horizon. Increasing Theratechnologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Theratechnologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Theratechnologies Stock. However, Theratechnologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  3.14 Real  2.47 Hype  3.14 Naive  3.22
The intrinsic value of Theratechnologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Theratechnologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
2.47
Real Value
7.41
Upside
Estimating the potential upside or downside of Theratechnologies helps investors to forecast how Theratechnologies stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Theratechnologies more accurately as focusing exclusively on Theratechnologies' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.463.033.61
Details
Hype
Prediction
LowEstimatedHigh
0.163.148.08
Details
Naive
Forecast
LowNext ValueHigh
0.063.228.16
Details

Theratechnologies Total Value Analysis

Theratechnologies is at this time anticipated to have valuation of 178.12 M with market capitalization of 144.38 M, debt of 45.61 M, and cash on hands of 36.46 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Theratechnologies fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
178.12 M
144.38 M
45.61 M
36.46 M

Theratechnologies Investor Information

About 48.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.19. Theratechnologies had not issued any dividends in recent years. The entity had 1:4 split on the 31st of July 2023. Based on the key indicators related to Theratechnologies' liquidity, profitability, solvency, and operating efficiency, Theratechnologies is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.

Theratechnologies Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Theratechnologies has an asset utilization ratio of 160.98 percent. This suggests that the Company is making $1.61 for each dollar of assets. An increasing asset utilization means that Theratechnologies is more efficient with each dollar of assets it utilizes for everyday operations.

Theratechnologies Ownership Allocation

Theratechnologies shows a total of 45.98 Million outstanding shares. 30% of Theratechnologies outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.

Theratechnologies Profitability Analysis

The company reported the previous year's revenue of 85.87 M. Net Loss for the year was (8.31 M) with profit before overhead, payroll, taxes, and interest of 70.02 M.

About Theratechnologies Valuation

Our relative valuation model uses a comparative analysis of Theratechnologies. We calculate exposure to Theratechnologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Theratechnologies's related companies.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company was incorporated in 1993 and is headquartered in Montreal, Canada. Theratechnologies operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 87 people.

Theratechnologies Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares Outstanding49.4 M
Forward Price Earnings55.8659

Additional Tools for Theratechnologies Stock Analysis

When running Theratechnologies' price analysis, check to measure Theratechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theratechnologies is operating at the current time. Most of Theratechnologies' value examination focuses on studying past and present price action to predict the probability of Theratechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theratechnologies' price. Additionally, you may evaluate how the addition of Theratechnologies to your portfolios can decrease your overall portfolio volatility.